Frazier O H, Delgado Reynolds M, Kar Biswajit, Patel Vijay, Gregoric Igor D, Myers Timothy J
The Department of Transplantation, Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, Texas 77030, USA.
Tex Heart Inst J. 2004;31(2):157-9.
Axial flow ventricular assist devices show great promise as a potential treatment for patients with end-stage heart failure. The HeartMate II system, redesigned on the basis of initial clinical experiences in Europe, is now in clinical trials in the United States. We report on the 1st use of the newly redesigned HeartMate II in the United States. The system has unique features, which include an accurate flow estimator and the ability to automatically detect and correct excessive left ventricular unloading. The new design also incorporates changes in the texturing of the blood-contacting surfaces to prevent thrombosis. The implantation technique and configuration are similar to those of the HeartMate XVE LVAS and require a median sternotomy for access. The 1st patient to receive the device in the United States has had an uncomplicated perioperative course and now awaits transplantation.
轴流心室辅助装置作为终末期心力衰竭患者的一种潜在治疗方法显示出巨大的前景。基于在欧洲的初步临床经验重新设计的HeartMate II系统目前正在美国进行临床试验。我们报告了美国首次使用新重新设计的HeartMate II的情况。该系统具有独特的特点，包括精确的流量估计器以及自动检测和纠正过度左心室卸载的能力。新设计还对血液接触表面的纹理进行了改变以防止血栓形成。植入技术和配置与HeartMate XVE左心室辅助系统相似，需要通过正中胸骨切开术进行操作。在美国首位接受该装置的患者围手术期过程顺利，目前正在等待移植。
